Cases & Deals

  • Home
  • Practices
  • LeaderMed Health Group expands pipeline with Aqualung license

Share

LeaderMed Health Group expands pipeline with Aqualung license

April 2022

Client(s) Leadermed Health Group Limited

Jones Day represented LeaderMed Health Group Limited in subscription of a convertible note and an exclusive license agreement with Aqualung Therapeutics Corporation ("Aqualung") to develop, manufacture, and commercialize Aqualung's clinical stage antibody product ALT-100 in eight Asian territories, including Greater China.

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.